SCA
MYGN icon

STALEY CAPITAL ADVISERS’s Myriad Genetics MYGN Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-32,894
Closed -$850K – 168
2017
Q2 		$850K Buy
+32,894
New +$698K 0.07% 84

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

STALEY CAPITAL ADVISERS's MYGN Position: Q3 2017 in Review

STALEY CAPITAL ADVISERS sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 32,894 shares — an estimated $850K sold.

STALEY CAPITAL ADVISERS first reported a position in MYGN in Q2 2017 and held it in 1 quarter. The position peaked at $850K in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • STALEY CAPITAL ADVISERS reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • STALEY CAPITAL ADVISERS sold 32,894 Myriad Genetics shares in Q3 2017, an estimated $850K.
  • STALEY CAPITAL ADVISERS first reported a position in Myriad Genetics in Q2 2017 and held it in 1 quarter.
  • STALEY CAPITAL ADVISERS's Myriad Genetics position peaked at $850K in Q2 2017.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2017, filed 9 Nov 2017.